Ann: PTX-100 to Re-enter Trials in Hematology Niche, page-7

Hi all, a re- visit to page 40 of the last investor presentation was of interest.
Although many already picked up on this, I missed it entirely (on holidays currently, hence more time to research).
The point of interest is the plus 20 times of transactions (2016 period) more on the current proposed ptx100 1b trail (in design) about to commence recruitment on the ‘x mutation oncology’ rare disease program.
With PTX in the forefront of pipeline deapth in this sort after ( current Pharma hot spot) area, again it reflects the scientific and business model of strategic encompassing the team of this gem of a company we chose to invest our hard earned capital in.